
Lijek Pharmaceuticals Private Limited
About Lijek Pharmaceuticals Private Limited
Data last updated:
Lijek Pharmaceuticals Private Limited is a private limited company based in Noida, Uttar Pradesh, India. It operates in the manufacturing segment of the chemicals sector. It was incorporated on 13 January 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Uttar Pradesh, under CIN U24233UP2016PTC075711.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Bashishth Kumar and Ashish Kumar Jha.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at D – 107 Hindon Vihar Barola, Noida, Uttar Pradesh, India – 201301.
As per the financials filed for FY 2025, the company reported a revenue of ₹72,400, a growth of 38% compared to the previous year. For the same year it recorded a net loss of ₹400 (net margin -0.6%) and EBITDA of -₹400 (EBITDA margin -0.6%). Revenue has grown at a compounded annual rate (CAGR) of 157% over three years and 9% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Lijek Pharmaceuticals Private Limited's registered office is in Noida, Uttar Pradesh. Its e-mail address is in the company report.
- Email
- Registered AddressD – 107 Hindon Vihar Barola, Noida, Uttar Pradesh, India – 201301
- IndustryChemicals, Manufacturing, Other Chemical Product
To see the full contact details of Lijek Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Lijek Pharmaceuticals Private Limited
FY 2025 filings availableLijek Pharmaceuticals Private Limited reported revenue of ₹72,400 (up 38% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 9% over five years, including 38% growth in the latest year. EBITDA fell 102% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹400 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹400 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -0.6% | ||||
| Net Profit Margin | -0.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Lijek Pharmaceuticals Private Limited, buy the company report.
Board of directors of Lijek Pharmaceuticals Private Limited
Lijek Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bashishth Kumar | Director | 13 Jan 2016 | 10 Years 9 Months | Current |
| Ashish Kumar Jha | Director | 13 Jan 2016 | 10 Years 9 Months | Current |
Peer comparison
Lijek Pharmaceuticals Private Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| TVR Pharmaceuticals Private Limited | ₹74,470 (FY 2024) | Hyderabad, Telangana, India | ||||
| Imedheal Pharmaceuticals Private Limited | ₹74,374 (FY 2022) | Sambhal, Uttar Pradesh, India | ||||
| B. C. Pharmaceuticals Private Limited | ₹73,203 (FY 2021) | -79.0% | Varanasi, Uttar Pradesh, India | |||
| Chemabelia Pharmaceuticals Private Limited | ₹73,144 (FY 2018) | -69.0% | Jaipur, Rajasthan, India | |||
| Lawrence Pharmaceuticals Private Limited | ₹73,000 (FY 2016) | -70.0% | Patna, Bihar, India | |||
| Lijek Pharmaceuticals Private Limitedthis company | ₹72,400 (FY 2025) | -₹400 | -0.6% | 38.0% | Noida, Uttar Pradesh, India | |
| Pinnace Pharmaceuticals Private Limited | ₹71,701 (FY 2022) | Zirakpur, Punjab, India | ||||
| Aerocure Pharmaceuticals Private Limited | ₹70,707 (FY 2024) | Delhi, India | ||||
| Vitthal Pharmaceuticals Private Limited | ₹69,976 (FY 2025) | -90.0% | Agra, Uttar Pradesh, India | |||
| Vindeep Pharmaceuticals Private Limited | ₹69,605 (FY 2025) | 26.0% | Thane, Maharashtra, India | |||
| Camerin Drugs and Pharmaceuticals Ltd | ₹69,127 (FY 2019) | -83.0% | Cannanore, Kerala, India |
To see the full peer comparison of Lijek Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Lijek Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Lijek Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Lijek Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Lijek Pharmaceuticals Private Limited has 2 board changes on record since 2016: 2 appointments. The latest: Ashish Kumar Jha was appointed as Director on 13 Jan 2016.
Frequently asked questions
Lijek Pharmaceuticals is an active private limited company based in Noida, Uttar Pradesh, India. The company works in manufacturing, within the chemicals industry. It was incorporated on 13 January 2016 (10+ years old) and is registered under CIN U24233UP2016PTC075711.
Lijek Pharmaceuticals has 2 current directors:
- Bashishth Kumar - Director
- Ashish Kumar Jha - Director
The latest financial statements of Lijek Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2016 are in the company report.
The CIN (Corporate Identification Number) of Lijek Pharmaceuticals is U24233UP2016PTC075711. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Lijek Pharmaceuticals was incorporated on 13 January 2016, making it 10+ years old. It is registered with the Registrar of Companies, Uttar Pradesh.
The peers of Lijek Pharmaceuticals by revenue are TVR Pharmaceuticals Private Limited, Imedheal Pharmaceuticals Private Limited, B. C. Pharmaceuticals Private Limited, Chemabelia Pharmaceuticals Private Limited, Lawrence Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharmaceuticals).
Ashish Kumar Jha was appointed as Director on 13 Jan 2016. Bashishth Kumar was appointed as Director on 13 Jan 2016.
The registered office of Lijek Pharmaceuticals is at D – 107 Hindon Vihar Barola, Noida, Uttar Pradesh, India – 201301.
Lijek Pharmaceuticals operates in the chemicals industry, in the manufacturing segment.
The compliance status of Lijek Pharmaceuticals is compliant as of 19 August 2026. The company is actively filing with the Registrar of Companies.
Lijek Pharmaceuticals can be reached at its registered office: D – 107 Hindon Vihar Barola, Noida, Uttar Pradesh, India – 201301.

